Steven I. Aronin
Research Subjects
Steven I. Aronin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Sailaja Puttagunta
Iterum Therapeutics, Old Saybrook, Connecticut, USA
6 shared publicationsMichael W. Dunne
Bill and Melinda Gates Medical Research Institute, Cambridge, MA 02139
3 shared publications- Michael W. Dunne
Iterum Therapeutics , Old Saybrook, Connecticut , USA
3 shared publications Karthik Akinapelli
Takeda, Cambridge, MA 02142
2 shared publicationsVikas Gupta
Becton, Dickinson and Company, Franklin Lakes, NJ, USA
2 shared publicationsAnita F Das
Das Statistical Consulting , Guerneville, California
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0039926
In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models
Bacillus anthracis is a gram-positive, spore-forming bacterium and the etiological agent of anthrax. As a Tier 1 Select Agent, the pathogen can be isolated from the natural environment, and the endospore is a significant biological threat that can be produced in large quantities, stored, and disseminated by aerosolization. The intentional release of B. anthracis spores has the potential for mass casualties and is a serious threat to public and military health. Fluoroquinolones and tetracyclines are common antibiotics used for post-exposure prophylaxis and treatment in the United States (U.S.), whereas penicillin is the drug of choice throughout the rest of the world. However, these commonly used antibiotics may be contraindicated or suboptimal in a public health crisis. Thus, there is a need for novel medical countermeasures to be developed and tested against B. anthracis . Sulopenem is a broad-spectrum, orally bioavailable penem antibiotic recently approved in the U.S. for the treatment of uncomplicated urinary tract infections in women with limited therapeutic options. Here, we demonstrate that sulopenem has potent in vitro activity against both wild-type virulent B. anthracis strains, as well as biosafety level 2 surrogate strains resistant to current standards of care. Using human-equivalent dosing regimens, we show that sulopenem is highly protective in both the mouse and rabbit inhalational anthrax models. Together, these results support continued evaluation of this oral penem as a countermeasure for inhalational anthrax.
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0039926
Open AccessIn vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models
Bacillus anthracis is a gram-positive, spore-forming bacterium and the etiological agent of anthrax. As a Tier 1 Select Agent, the pathogen can be isolated from the natural environment, and the endospore is a significant biological threat that can be produced in large quantities, stored, and disseminated by aerosolization. The intentional release of B. anthracis spores has the potential for mass casualties and is a serious threat to public and military health. Fluoroquinolones and tetracyclines are common antibiotics used for post-exposure prophylaxis and treatment in the United States (U.S.), whereas penicillin is the drug of choice throughout the rest of the world. However, these commonly used antibiotics may be contraindicated or suboptimal in a public health crisis. Thus, there is a need for novel medical countermeasures to be developed and tested against B. anthracis . Sulopenem is a broad-spectrum, orally bioavailable penem antibiotic recently approved in the U.S. for the treatment of uncomplicated urinary tract infections in women with limited therapeutic options. Here, we demonstrate that sulopenem has potent in vitro activity against both wild-type virulent B. anthracis strains, as well as biosafety level 2 surrogate strains resistant to current standards of care. Using human-equivalent dosing regimens, we show that sulopenem is highly protective in both the mouse and rabbit inhalational anthrax models. Together, these results support continued evaluation of this oral penem as a countermeasure for inhalational anthrax.
- Open Access
- 22 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 152-159
In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
- 22 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 152-159
Open AccessIn vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
- Open Access
- 4 March 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (3) , e0189824
Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated in vitro antimicrobial activity of sulopenem by post-antibiotic effect (PAE), sub-inhibitory minimal inhibitory concentration PAE effect (PAE-SME), checkerboard testing, and time-kill testing. Testing sulopenem at 1×, 5×, or 10× the baseline MIC resulted in a PAE interval of 0.0–0.7 hours. When exposed to 0.5× the sulopenem MIC following 5× MIC, all isolate/agent combinations had PAE-SME values of >4.8 hours. Checkerboard testing revealed no instances of antagonism between sulopenem and comparator agents—indifference was observed in most sulopenem checkerboard combinations. Sulopenem demonstrated bactericidal activity (≥3 log 10 [99.9%] reduction in viable organism counts) in all time-kill assays following 24 hours of incubation at 8× the baseline MIC (6/6), 5/6 displaying this activity within 8 hours. The present antimicrobial parameters seen at concentrations surrounding the MIC support optimization of sulopenem dosing and further development. The oral dosing regimen of sulopenem etzadroxil/probenecid 500 mg/500 mg administered every 12 hours was recently evaluated in two phase 3 clinical trials where sulopenem demonstrated efficacy against amoxicillin-clavulanate in uncomplicated urinary tract infection (uUTI) and against ciprofloxacin in fluoroquinolone-resistant uUTI. IMPORTANCE: Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated sulopenem via broth microdilution susceptibility testing, PAE, sub-inhibitory MIC PAE effect, checkerboard testing, and time-kill testing. The results of this study—interpreted along with recent pharmacodynamic in vitro one-compartment and hollow-fiber infection model work—provide insight into the in vitro activity of sulopenem.
- 4 March 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (3) , e0189824
Open AccessCharacterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated in vitro antimicrobial activity of sulopenem by post-antibiotic effect (PAE), sub-inhibitory minimal inhibitory concentration PAE effect (PAE-SME), checkerboard testing, and time-kill testing. Testing sulopenem at 1×, 5×, or 10× the baseline MIC resulted in a PAE interval of 0.0–0.7 hours. When exposed to 0.5× the sulopenem MIC following 5× MIC, all isolate/agent combinations had PAE-SME values of >4.8 hours. Checkerboard testing revealed no instances of antagonism between sulopenem and comparator agents—indifference was observed in most sulopenem checkerboard combinations. Sulopenem demonstrated bactericidal activity (≥3 log 10 [99.9%] reduction in viable organism counts) in all time-kill assays following 24 hours of incubation at 8× the baseline MIC (6/6), 5/6 displaying this activity within 8 hours. The present antimicrobial parameters seen at concentrations surrounding the MIC support optimization of sulopenem dosing and further development. The oral dosing regimen of sulopenem etzadroxil/probenecid 500 mg/500 mg administered every 12 hours was recently evaluated in two phase 3 clinical trials where sulopenem demonstrated efficacy against amoxicillin-clavulanate in uncomplicated urinary tract infection (uUTI) and against ciprofloxacin in fluoroquinolone-resistant uUTI. IMPORTANCE: Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated sulopenem via broth microdilution susceptibility testing, PAE, sub-inhibitory MIC PAE effect, checkerboard testing, and time-kill testing. The results of this study—interpreted along with recent pharmacodynamic in vitro one-compartment and hollow-fiber infection model work—provide insight into the in vitro activity of sulopenem.
- Open Access
- 2 November 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (3) , 396-401
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections
- 2 November 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (3) , 396-401
Open AccessA phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections
- Open Access
- 20 July 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (7) , e0024623
Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
Sulopenem disk masses of 2, 5, 10, and 20 μg were evaluated by susceptibility testing isolates by broth microdilution and disk diffusion. A 2-μg disk was chosen, and error-rate bounding analysis in accordance with Clinical and Laboratory Standards Institute (CLSI) guideline M23 was conducted using a proposed sulopenem susceptible/intermediate/resistant (S/I/R) interpretive criterion of ≤0.5/1/≥2 μg/mL.
- 20 July 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (7) , e0024623
Open AccessSulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
Sulopenem disk masses of 2, 5, 10, and 20 μg were evaluated by susceptibility testing isolates by broth microdilution and disk diffusion. A 2-μg disk was chosen, and error-rate bounding analysis in accordance with Clinical and Laboratory Standards Institute (CLSI) guideline M23 was conducted using a proposed sulopenem susceptible/intermediate/resistant (S/I/R) interpretive criterion of ≤0.5/1/≥2 μg/mL.
- Open Access
- 28 March 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (1) , 159-161
Applying Desirability of Outcome Ranking End Points
To the Editor—We conducted a phase 3 trial in patients with uncomplicated urinary tract infection (UTI), comparing oral sulopenem etzadroxil + probenecid with oral ciprofloxacin [ 1], and we used the Food and Drug Administration's definition of overall success in studies of UTI, one that requires both clinical cure and microbiologic eradication. In the population of patients with uropathogens that were nonsusceptible to ciprofloxacin, sulopenem was superior to ciprofloxacin (62.6% vs 36.0%; difference, 26.6% [95% confidence interval (CI), 15.1%–37.4%]; P < .001). In the patients with ciprofloxacin-susceptible isolates, sulopenem was not noninferior to ciprofloxacin (66.8% vs 78.6%; difference, −11.8% [95% CI, −18.0 to −5.6). This difference could be attributed to a higher rate of asymptomatic bacteriuria after treatment in patients on sulopenem. In the analysis of all patients, sulopenem was noninferior to ciprofloxacin (65.6% vs 67.9%; difference, −2.3% [95% CI, −7.9 to 3.3]).
- 28 March 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (1) , 159-161
Open AccessApplying Desirability of Outcome Ranking End Points
To the Editor—We conducted a phase 3 trial in patients with uncomplicated urinary tract infection (UTI), comparing oral sulopenem etzadroxil + probenecid with oral ciprofloxacin [ 1], and we used the Food and Drug Administration's definition of overall success in studies of UTI, one that requires both clinical cure and microbiologic eradication. In the population of patients with uropathogens that were nonsusceptible to ciprofloxacin, sulopenem was superior to ciprofloxacin (62.6% vs 36.0%; difference, 26.6% [95% confidence interval (CI), 15.1%–37.4%]; P < .001). In the patients with ciprofloxacin-susceptible isolates, sulopenem was not noninferior to ciprofloxacin (66.8% vs 78.6%; difference, −11.8% [95% CI, −18.0 to −5.6). This difference could be attributed to a higher rate of asymptomatic bacteriuria after treatment in patients on sulopenem. In the analysis of all patients, sulopenem was noninferior to ciprofloxacin (65.6% vs 67.9%; difference, −2.3% [95% CI, −7.9 to 3.3]).
- Open Access
- 28 April 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 103 (4) , 115717
Increased rates of extended-spectrum beta-lactamase isolates in patients hospitalized with culture-positive urinary Enterobacterales in the United States: 2011 – 2020
- 28 April 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 103 (4) , 115717
Open AccessIncreased rates of extended-spectrum beta-lactamase isolates in patients hospitalized with culture-positive urinary Enterobacterales in the United States: 2011 – 2020
- Open Access
- 23 February 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (1) , e0235921
Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
Resistance rates for bacteria that cause urinary tract infections (UTIs) have increased dramatically. Regional rates of resistance to commonly prescribed antibiotics now exceed 20%, which is the threshold at which the Infectious Diseases Society of America recommends therapy be guided by culture.
- 23 February 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (1) , e0235921
Open AccessImpact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
Resistance rates for bacteria that cause urinary tract infections (UTIs) have increased dramatically. Regional rates of resistance to commonly prescribed antibiotics now exceed 20%, which is the threshold at which the Infectious Diseases Society of America recommends therapy be guided by culture.